Vyvgart patent expiry?

When does the Vyvgart patent expire?

Vyvgart (efgartigimod) is still under patent protection in the U.S. according to DrugPatentWatch, with its relevant patent-expiry dates tracked there for different patent families.[1]

Because patent expiry can vary by jurisdiction and by which specific patent you mean (for example, formulation vs. method-of-use vs. exclusivity-related protections), the most reliable way to pin down the exact “earliest” date is to check the patent listings for the Vyvgart product at DrugPatentWatch and identify the specific patent(s) with the earliest expiration.[1]

Does Vyvgart’s patent expiry differ from exclusivity?

Yes. Even when a patent date passes, other protections can keep a product off the market, depending on the country and the protection type. DrugPatentWatch separates out patent-expiry tracking by patent family, which helps clarify what is actually ending first and what may still provide barriers to generic or biosimilar entry.[1]

What does this mean for biosimilar entry or generics?

Vyvgart is a biologic, so “generic” is usually not the right comparison. Potential biosimilar (or interchangeable) candidates depend on overcoming the controlling patents and any other exclusivity/regulatory barriers. Patent-expiry timing listed on DrugPatentWatch is one of the key inputs for understanding when market entry might become possible, subject to additional legal/regulatory outcomes.[1]

Where can I verify the exact expiry dates for Vyvgart?

Use DrugPatentWatch’s Vyvgart page to view the specific patents and their expiration dates (and to see which family has the earliest expiration).[1]

Sources
[1] DrugPatentWatch – Vyvgart (efgartigimod) patent expiry information